DEXCOM INC (DXCM) Fundamental Analysis & Valuation

NASDAQ:DXCM • US2521311074

Current stock price

61.54 USD
-1.41 (-2.24%)
At close:
62 USD
+0.46 (+0.75%)
Pre-Market:

This DXCM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. DXCM Profitability Analysis

1.1 Basic Checks

  • DXCM had positive earnings in the past year.
  • In the past year DXCM had a positive cash flow from operations.
  • Each year in the past 5 years DXCM has been profitable.
  • In the past 5 years DXCM always reported a positive cash flow from operatings.
DXCM Yearly Net Income VS EBIT VS OCF VS FCFDXCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

1.2 Ratios

  • The Return On Assets of DXCM (13.19%) is better than 93.62% of its industry peers.
  • DXCM has a better Return On Equity (30.46%) than 96.81% of its industry peers.
  • The Return On Invested Capital of DXCM (18.92%) is better than 96.81% of its industry peers.
  • DXCM had an Average Return On Invested Capital over the past 3 years of 14.59%. This is significantly above the industry average of 9.15%.
  • The last Return On Invested Capital (18.92%) for DXCM is above the 3 year average (14.59%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 13.19%
ROE 30.46%
ROIC 18.92%
ROA(3y)10.24%
ROA(5y)8.29%
ROE(3y)28.01%
ROE(5y)22.13%
ROIC(3y)14.59%
ROIC(5y)11.66%
DXCM Yearly ROA, ROE, ROICDXCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 -20 30

1.3 Margins

  • DXCM's Profit Margin of 17.94% is amongst the best of the industry. DXCM outperforms 93.09% of its industry peers.
  • In the last couple of years the Profit Margin of DXCM has declined.
  • The Operating Margin of DXCM (21.55%) is better than 93.62% of its industry peers.
  • DXCM's Operating Margin has improved in the last couple of years.
  • DXCM has a better Gross Margin (62.09%) than 65.43% of its industry peers.
  • In the last couple of years the Gross Margin of DXCM has declined.
Industry RankSector Rank
OM 21.55%
PM (TTM) 17.94%
GM 62.09%
OM growth 3Y15.68%
OM growth 5Y5.09%
PM growth 3Y15.23%
PM growth 5Y-8.86%
GM growth 3Y-1.61%
GM growth 5Y-1.72%
DXCM Yearly Profit, Operating, Gross MarginsDXCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. DXCM Health Analysis

2.1 Basic Checks

  • DXCM has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • DXCM has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DXCM remains at a similar level compared to 5 years ago.
  • Compared to 1 year ago, DXCM has an improved debt to assets ratio.
DXCM Yearly Shares OutstandingDXCM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
DXCM Yearly Total Debt VS Total AssetsDXCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • DXCM has an Altman-Z score of 6.11. This indicates that DXCM is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.11, DXCM belongs to the top of the industry, outperforming 80.85% of the companies in the same industry.
  • DXCM has a debt to FCF ratio of 1.20. This is a very positive value and a sign of high solvency as it would only need 1.20 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.20, DXCM belongs to the top of the industry, outperforming 89.89% of the companies in the same industry.
  • DXCM has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
  • DXCM's Debt to Equity ratio of 0.47 is in line compared to the rest of the industry. DXCM outperforms 42.02% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 1.2
Altman-Z 6.11
ROIC/WACC2.29
WACC8.27%
DXCM Yearly LT Debt VS Equity VS FCFDXCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • A Current Ratio of 1.88 indicates that DXCM should not have too much problems paying its short term obligations.
  • The Current ratio of DXCM (1.88) is worse than 66.49% of its industry peers.
  • DXCM has a Quick Ratio of 1.59. This is a normal value and indicates that DXCM is financially healthy and should not expect problems in meeting its short term obligations.
  • DXCM has a Quick ratio of 1.59. This is comparable to the rest of the industry: DXCM outperforms 40.96% of its industry peers.
  • DXCM does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.59
DXCM Yearly Current Assets VS Current LiabilitesDXCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. DXCM Growth Analysis

3.1 Past

  • DXCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.73%, which is quite good.
  • DXCM shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.29% yearly.
  • The Revenue has grown by 15.60% in the past year. This is quite good.
  • DXCM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.33% yearly.
EPS 1Y (TTM)12.73%
EPS 3Y28.82%
EPS 5Y19.29%
EPS Q2Q%0%
Revenue 1Y (TTM)15.6%
Revenue growth 3Y17.01%
Revenue growth 5Y19.33%
Sales Q2Q%13.12%

3.2 Future

  • The Earnings Per Share is expected to grow by 21.71% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, DXCM will show a quite strong growth in Revenue. The Revenue will grow by 11.94% on average per year.
EPS Next Y36.73%
EPS Next 2Y27.84%
EPS Next 3Y25.1%
EPS Next 5Y21.71%
Revenue Next Year12.62%
Revenue Next 2Y12.47%
Revenue Next 3Y12.38%
Revenue Next 5Y11.94%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
DXCM Yearly Revenue VS EstimatesDXCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B 10B
DXCM Yearly EPS VS EstimatesDXCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

6

4. DXCM Valuation Analysis

4.1 Price/Earnings Ratio

  • DXCM is valuated quite expensively with a Price/Earnings ratio of 33.09.
  • DXCM's Price/Earnings ratio is a bit cheaper when compared to the industry. DXCM is cheaper than 71.28% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of DXCM to the average of the S&P500 Index (27.38), we can say DXCM is valued slightly more expensively.
  • DXCM is valuated rather expensively with a Price/Forward Earnings ratio of 24.20.
  • Based on the Price/Forward Earnings ratio, DXCM is valued a bit cheaper than 75.53% of the companies in the same industry.
  • DXCM is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 38.20, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 33.09
Fwd PE 24.2
DXCM Price Earnings VS Forward Price EarningsDXCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, DXCM is valued a bit cheaper than the industry average as 76.06% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, DXCM is valued cheaper than 87.77% of the companies in the same industry.
Industry RankSector Rank
P/FCF 21.99
EV/EBITDA 17.43
DXCM Per share dataDXCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • DXCM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • DXCM has an outstanding profitability rating, which may justify a higher PE ratio.
  • DXCM's earnings are expected to grow with 25.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.9
PEG (5Y)1.72
EPS Next 2Y27.84%
EPS Next 3Y25.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DXCM Dividend Analysis

5.1 Amount

  • No dividends for DXCM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DXCM Fundamentals: All Metrics, Ratios and Statistics

DEXCOM INC

NASDAQ:DXCM (4/15/2026, 8:00:02 PM)

Premarket: 62 +0.46 (+0.75%)

61.54

-1.41 (-2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)04-30
Inst Owners101.29%
Inst Owner Change0.05%
Ins Owners0.25%
Ins Owner Change9.44%
Market Cap23.68B
Revenue(TTM)4.66B
Net Income(TTM)836.30M
Analysts84.86
Price Target89.43 (45.32%)
Short Float %3.84%
Short Ratio3.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.4%
Min EPS beat(2)-32.12%
Max EPS beat(2)5.32%
EPS beat(4)2
Avg EPS beat(4)-6.03%
Min EPS beat(4)-32.12%
Max EPS beat(4)6.77%
EPS beat(8)5
Avg EPS beat(8)-1.11%
EPS beat(12)9
Avg EPS beat(12)9.15%
EPS beat(16)11
Avg EPS beat(16)5.86%
Revenue beat(2)1
Avg Revenue beat(2)-0.14%
Min Revenue beat(2)-0.9%
Max Revenue beat(2)0.61%
Revenue beat(4)2
Avg Revenue beat(4)0.1%
Min Revenue beat(4)-0.9%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-1.02%
Revenue beat(12)5
Avg Revenue beat(12)-0.35%
Revenue beat(16)6
Avg Revenue beat(16)-0.53%
PT rev (1m)1.24%
PT rev (3m)1.01%
EPS NQ rev (1m)0.17%
EPS NQ rev (3m)-0.14%
EPS NY rev (1m)0.03%
EPS NY rev (3m)0.86%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-0.66%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-0.04%
Valuation
Industry RankSector Rank
PE 33.09
Fwd PE 24.2
P/S 5.08
P/FCF 21.99
P/OCF 16.44
P/B 8.63
P/tB 8.93
EV/EBITDA 17.43
EPS(TTM)1.86
EY3.02%
EPS(NY)2.54
Fwd EY4.13%
FCF(TTM)2.8
FCFY4.55%
OCF(TTM)3.74
OCFY6.08%
SpS12.11
BVpS7.14
TBVpS6.89
PEG (NY)0.9
PEG (5Y)1.72
Graham Number17.2801 (-71.92%)
Profitability
Industry RankSector Rank
ROA 13.19%
ROE 30.46%
ROCE 23.93%
ROIC 18.92%
ROICexc 36.12%
ROICexgc 37.75%
OM 21.55%
PM (TTM) 17.94%
GM 62.09%
FCFM 23.11%
ROA(3y)10.24%
ROA(5y)8.29%
ROE(3y)28.01%
ROE(5y)22.13%
ROIC(3y)14.59%
ROIC(5y)11.66%
ROICexc(3y)37.89%
ROICexc(5y)31.72%
ROICexgc(3y)41.79%
ROICexgc(5y)35.48%
ROCE(3y)18.46%
ROCE(5y)14.75%
ROICexgc growth 3Y1.89%
ROICexgc growth 5Y6.96%
ROICexc growth 3Y7.33%
ROICexc growth 5Y6.44%
OM growth 3Y15.68%
OM growth 5Y5.09%
PM growth 3Y15.23%
PM growth 5Y-8.86%
GM growth 3Y-1.61%
GM growth 5Y-1.72%
F-Score8
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 1.2
Debt/EBITDA 1.03
Cap/Depr 144.36%
Cap/Sales 7.8%
Interest Coverage 88.12
Cash Conversion 114.67%
Profit Quality 128.81%
Current Ratio 1.88
Quick Ratio 1.59
Altman-Z 6.11
F-Score8
WACC8.27%
ROIC/WACC2.29
Cap/Depr(3y)145.46%
Cap/Depr(5y)210.39%
Cap/Sales(3y)7.74%
Cap/Sales(5y)10.33%
Profit Quality(3y)110.93%
Profit Quality(5y)89.33%
High Growth Momentum
Growth
EPS 1Y (TTM)12.73%
EPS 3Y28.82%
EPS 5Y19.29%
EPS Q2Q%0%
EPS Next Y36.73%
EPS Next 2Y27.84%
EPS Next 3Y25.1%
EPS Next 5Y21.71%
Revenue 1Y (TTM)15.6%
Revenue growth 3Y17.01%
Revenue growth 5Y19.33%
Sales Q2Q%13.12%
Revenue Next Year12.62%
Revenue Next 2Y12.47%
Revenue Next 3Y12.38%
Revenue Next 5Y11.94%
EBIT growth 1Y53.73%
EBIT growth 3Y35.36%
EBIT growth 5Y25.41%
EBIT Next Year67.73%
EBIT Next 3Y32.66%
EBIT Next 5Y25.77%
FCF growth 1Y70.79%
FCF growth 3Y52.34%
FCF growth 5Y31.25%
OCF growth 1Y45.6%
OCF growth 3Y29.1%
OCF growth 5Y24.81%

DEXCOM INC / DXCM Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for DEXCOM INC?

ChartMill assigns a fundamental rating of 7 / 10 to DXCM.


What is the valuation status of DEXCOM INC (DXCM) stock?

ChartMill assigns a valuation rating of 6 / 10 to DEXCOM INC (DXCM). This can be considered as Fairly Valued.


What is the profitability of DXCM stock?

DEXCOM INC (DXCM) has a profitability rating of 8 / 10.


How financially healthy is DEXCOM INC?

The financial health rating of DEXCOM INC (DXCM) is 8 / 10.